BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012;19:1439-1445. [PMID: 22187121 DOI: 10.1245/s10434-011-2173-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Lázár G. [Intestinal surgery]. Magy Seb 2012;65:116-28. [PMID: 22717966 DOI: 10.1556/MaSeb.65.2012.3.6] [Reference Citation Analysis]
2 Cloyd JM, George E, Visser BC. Duodenal adenocarcinoma: Advances in diagnosis and surgical management. World J Gastrointest Surg 2016; 8(3): 212-221 [PMID: 27022448 DOI: 10.4240/wjgs.v8.i3.212] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
3 Matsuo Y, Yamamoto H, Sato Y, Oikawa R, Maehata T, Fujino T, Yahagi N, Yasuda H, Takagi M, Itoh F. GNAS-mutated carcinoma arising from gastric foveolar metaplasia in the duodenum after 9 years of observation. Clin J Gastroenterol 2018;11:391-5. [DOI: 10.1007/s12328-018-0856-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Nitta N, Ohgi K, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Sasaki K, Uesaka K. Prognostic Impact of Pancreatic Invasion in Duodenal Carcinoma: A Single-Center Experience. Ann Surg Oncol 2020;27:4553-60. [PMID: 32367502 DOI: 10.1245/s10434-020-08512-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Aparicio T, Henriques J, Manfredi S, Tougeron D, Bouché O, Pezet D, Piessen G, Coriat R, Zaanan A, Legoux JL, Terrebone E, Pocard M, Gornet JM, Lecomte T, Lombard-Bohas C, Perrier H, Lecaille C, Lavau-Denes S, Vernerey D, Afchain P; NADEGE Investigators. Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients. Int J Cancer 2020;147:967-77. [PMID: 31912484 DOI: 10.1002/ijc.32860] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
6 Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, Kasper P, Bruns C, Brunn A, Roth W, Hartmann N, Bunck A, Schmidt M, Buettner R, Merkelbach-Bruse S. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. BMC Gastroenterol 2019;19:21. [PMID: 30717682 DOI: 10.1186/s12876-019-0942-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
7 Amano T, Iijima H, Shinzaki S, Tashiro T, Iwatani S, Tani M, Otake Y, Yoshihara T, Sugimoto A, Egawa S, Yamaguchi S, Kinoshita K, Araki M, Hirao M, Sakakibara Y, Hiyama S, Ogawa H, Nagaike K, Murata J, Komori M, Okuda Y, Kizu T, Tsujii Y, Hayashi Y, Inoue T, Takahashi H, Mizushima T, Morii E, Takehara T. Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma. BMC Cancer 2021;21:978. [PMID: 34465291 DOI: 10.1186/s12885-021-08724-5] [Reference Citation Analysis]
8 Gelsomino F, Balsano R, De Lorenzo S, Garajová I. Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management. Current Oncology 2022;29:1223-36. [DOI: 10.3390/curroncol29020104] [Reference Citation Analysis]
9 Vanoli A, Grillo F, Guerini C, Neri G, Arpa G, Klersy C, Nesi G, Giuffrida P, Sampietro G, Ardizzone S, Fociani P, Fiocca R, Latella G, Sessa F, D'Errico A, Malvi D, Mescoli C, Rugge M, Ferrero S, Poggioli G, Rizzello F, Macciomei MC, Santini D, Volta U, De Giorgio R, Caio G, Calabrò A, Ciacci C, D'Armiento M, Rizzo A, Solina G, Martino M, Tonelli F, Villanacci V, Cannizzaro R, Canzonieri V, Florena AM, Biancone L, Monteleone G, Caronna R, Ciardi A, Elli L, Caprioli F, Vecchi M, D'Incà R, Zingone F, D'Odorico A, Lenti MV, Oreggia B, Reggiani Bonetti L, Giannone AG, Orlandi A, Barresi V, Ciccocioppo R, Amodeo G, Biletta E, Luinetti O, Pedrazzoli P, Pietrabissa A, Corazza GR, Solcia E, Paulli M, Di Sabatino A. Prognostic Role of Mismatch Repair Status, Histotype and High-Risk Pathologic Features in Stage II Small Bowel Adenocarcinomas. Ann Surg Oncol 2021;28:1167-77. [PMID: 32761330 DOI: 10.1245/s10434-020-08926-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Donisi G, Capretti G, Cortese N, Rigamonti A, Gavazzi F, Nappo G, Pulvirenti A, Sollai M, Spaggiari P, Zerbi A, Marchesi F. Immune infiltrating cells in duodenal cancers. J Transl Med 2020;18:340. [PMID: 32883314 DOI: 10.1186/s12967-020-02508-4] [Reference Citation Analysis]
11 Young JI, Mongoue-tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC, Tsikitis VL. Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. Diseases of the Colon & Rectum 2016;59:306-15. [DOI: 10.1097/dcr.0000000000000562] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
12 Pelizzaro F, Marsilio I, Fassan M, Piazza F, Barberio B, D'Odorico A, Savarino EV, Farinati F, Zingone F. The Risk of Malignancies in Celiac Disease-A Literature Review. Cancers (Basel) 2021;13:5288. [PMID: 34771450 DOI: 10.3390/cancers13215288] [Reference Citation Analysis]
13 Ota R, Sawada T, Tsuyama S, Sasaki Y, Suzuki H, Kaizaki Y, Hasatani K, Yamamoto E, Nakanishi H, Inagaki S, Tsuji S, Yoshida N, Doyama H, Minato H, Nakamura K, Kasashima S, Kubota E, Kataoka H, Tokino T, Yao T, Minamoto T. Integrated genetic and epigenetic analysis of cancer-related genes in non-ampullary duodenal adenomas and intramucosal adenocarcinomas. J Pathol 2020;252:330-42. [PMID: 32770675 DOI: 10.1002/path.5529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Chen ZH, Qiu MZ, Wu XY, Wu QN, Lu JH, Zeng ZL, Wang Y, Wei XL, Wang F, Xu RH. Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients. J Cancer 2018;9:512-20. [PMID: 29483956 DOI: 10.7150/jca.22305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, Locher C, Afchain P. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46:97-104. [PMID: 23796552 DOI: 10.1016/j.dld.2013.04.013] [Cited by in Crossref: 142] [Cited by in F6Publishing: 105] [Article Influence: 15.8] [Reference Citation Analysis]
16 Kim CJ, Baruch-oren T, Lin F, Fan X(, Yang XJ, Wang HL. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas. J Clin Pathol 2016;69:1046-50. [DOI: 10.1136/jclinpath-2015-203588] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
17 Cloyd JM, Norton JA, Visser BC, Poultsides GA. Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases. Ann Surg Oncol. 2015;22:573-580. [PMID: 25160736 DOI: 10.1245/s10434-014-4020-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
18 Khosla D, Dey T, Madan R, Gupta R, Goyal S, Kumar N, Kapoor R. Small bowel adenocarcinoma: An overview. World J Gastrointest Oncol 2022; 14(2): 413-422 [DOI: 10.4251/wjgo.v14.i2.413] [Reference Citation Analysis]
19 Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 2017;3:1546-53. [PMID: 28617917 DOI: 10.1001/jamaoncol.2017.1051] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 13.8] [Reference Citation Analysis]
20 Wang N, Bu Q, Liu Q, Yang J, He H, Liu J, Ren X, Lyu J. Effect of marital status on duodenal adenocarcinoma survival: A Surveillance Epidemiology and End Results population analysis. Oncol Lett 2019;18:1904-14. [PMID: 31423260 DOI: 10.3892/ol.2019.10475] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Kawai H, Haruki K, Takada N, Iino T, Ikegami M, Yanaga K. Small bowel adenocarcinoma incarcerated within an inguinal hernia. Surg Case Rep 2019;5:205. [PMID: 31883032 DOI: 10.1186/s40792-019-0765-8] [Reference Citation Analysis]
22 Rompteaux P, Gagnière J, Gornet JM, Coriat R, Baumgaertner I, Lecomte T, Afchain P, Zaanan A, Pocard M, Bachet JB, Bonichon-Lamichhane N, Bouché O, Faucheron JL, Forestier J, Lecaille C, Manfredi S, Tougeron D, Terrebonne E, Chehimi M, Villing AL, Sarda C, Legoux JL, Benamouzig R, Aparicio T. Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. Eur J Surg Oncol 2019;45:331-5. [PMID: 30501999 DOI: 10.1016/j.ejso.2018.11.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Cordova-Delgado M, Pizarro G, Pinto MP, Herrera ME, Garrido M. Case Report: Molecular Features and Treatment Options for Small Bowel Adenocarcinoma. Front Oncol 2021;11:593561. [PMID: 33777741 DOI: 10.3389/fonc.2021.593561] [Reference Citation Analysis]
24 Kim JW, Jun SY, Ylaya K, Chang HK, Oh YH, Hong SM, Chung JY, Hewitt SM. Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients. Front Oncol 2020;10:1427. [PMID: 32974155 DOI: 10.3389/fonc.2020.01427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Venkatachalam A, Pikarsky E, Ben-Neriah Y. Putative homeostatic role of cancer driver mutations. Trends Cell Biol 2021:S0962-8924(21)00142-2. [PMID: 34373150 DOI: 10.1016/j.tcb.2021.07.002] [Reference Citation Analysis]
26 Halfdanarson TR, Grothey A. Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned. Oncologist 2012;17:1133-4. [PMID: 22923454 DOI: 10.1634/theoncologist.2012-0323] [Reference Citation Analysis]
27 Ye X, Wang L, Xing Y, Song C. Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases. BMC Gastroenterol 2020;20:342. [PMID: 33059631 DOI: 10.1186/s12876-020-01487-6] [Reference Citation Analysis]
28 Lim YJ, Kim K. Effect of postoperative radiotherapy on survival in duodenal adenocarcinoma: a propensity score-adjusted analysis of Surveillance, Epidemiology, and End Results database. Int J Clin Oncol 2018;23:473-81. [DOI: 10.1007/s10147-017-1226-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TRJ. Small Bowel Adenocarcinoma. Gastroenterology Clinics of North America 2016;45:447-57. [DOI: 10.1016/j.gtc.2016.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
30 Zhao P, Chen H, Wen D, Mou S, Zhang F, Zheng S. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma. Cancer Commun (Lond) 2018;38:54. [PMID: 30139386 DOI: 10.1186/s40880-018-0323-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
31 Zheng Y, Yang P, Chen J, Yu K, Ye Y, Zhang L, Hou X, Wang D. Endoscopic excision as a viable alternative to major resection for early duodenal cancers: A population-based cohort study. Int J Surg 2022;101:106644. [PMID: 35500880 DOI: 10.1016/j.ijsu.2022.106644] [Reference Citation Analysis]
32 Zaaimi Y, Aparicio T, Laurent-Puig P, Taieb J, Zaanan A. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. Clin Res Hepatol Gastroenterol. 2016;40:154-160. [PMID: 26547136 DOI: 10.1016/j.clinre.2015.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
33 Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res 2019;25:641-51. [PMID: 30352910 DOI: 10.1158/1078-0432.CCR-18-1480] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zhang G, Lin L, Dong D, Qiu H, Liu T, Lian L, Shen G. Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report. Medicine (Baltimore) 2021;100:e24295. [PMID: 33530218 DOI: 10.1097/MD.0000000000024295] [Reference Citation Analysis]
35 Bojesen RD, Andersson M, Riis LB, Nielsen OH, Jess T. Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994-2010: a population-based study. J Gastroenterol 2016;51:891-9. [PMID: 26847562 DOI: 10.1007/s00535-016-1171-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Pan H, Cheng H, Wang H, Ge W, Yuan M, Jiang S, Wan X, Dong Y, Liu Z, Zhao R, Fang Y, Lou F, Cao S, Han W. Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma. Cancer Sci 2021;112:4758-71. [PMID: 34449929 DOI: 10.1111/cas.15119] [Reference Citation Analysis]
37 Overman MJ. Rare but real: management of small bowel adenocarcinoma. Am Soc Clin Oncol Educ Book 2013;:189-93. [PMID: 23714497 DOI: 10.14694/EdBook_AM.2013.33.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
38 Varshney VK, Varshney B, Khera S, Sureka B. Adenocarcinoma of the fourth portion of duodenum presenting as intussusception: an unusual manifestation of rare pathology. BMJ Case Rep 2021;14:e244034. [PMID: 34261636 DOI: 10.1136/bcr-2021-244034] [Reference Citation Analysis]
39 Coit DG, Kelsen D, Tang LH, Erasmus JJ, Gerdes H, Hofstetter WL. Small Intestine. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 221-34. [DOI: 10.1007/978-3-319-40618-3_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
40 Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, Thirot-Bidault A, Sobhani I, Malka D, Lecomte T, Locher C, Bonnetain F, Laurent-Puig P. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer 2013;109:3057-66. [PMID: 24196786 DOI: 10.1038/bjc.2013.677] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
41 Dell'Aquila E, Zeppola T, Stellato M, Pantano F, Scartozzi M, Madaudo C, Pietrantonio F, Cremolini C, Aprile G, Vincenzi B, Moretto R, Puzzoni M, Garattini SK, Lobefaro R, Tonini G, Santini D. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? Clin Med Insights Oncol 2020;14:1179554920946693. [PMID: 32821190 DOI: 10.1177/1179554920946693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
42 Wilhelm A, Galata C, Beutner U, Schmied BM, Warschkow R, Steffen T, Brunner W, Post S, Marti L. Duodenal localization is a negative predictor of survival after small bowel adenocarcinoma resection: A population-based, propensity score-matched analysis. J Surg Oncol 2018;117:397-408. [DOI: 10.1002/jso.24877] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
43 Xia M, Singhi AD, Dudley B, Brand R, Nikiforova M, Pai RK. Small Bowel Adenocarcinoma Frequently Exhibits Lynch Syndrome–associated Mismatch Repair Protein Deficiency But Does Not Harbor Sporadic MLH1 Deficiency. Applied Immunohistochemistry & Molecular Morphology 2017;25:399-406. [DOI: 10.1097/pai.0000000000000389] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Yu IS, Al-Hashami Z, Chapani P, Speers C, Davies JM, Lim HJ, Renouf DJ, Gill S, Stuart HC, Loree JM. Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers. Clin Colorectal Cancer 2021:S1533-0028(21)00129-8. [PMID: 34972663 DOI: 10.1016/j.clcc.2021.11.006] [Reference Citation Analysis]
45 Genta RM, Feagins LA. Advanced precancerous lesions in the small bowel mucosa. Best Practice & Research Clinical Gastroenterology 2013;27:225-33. [DOI: 10.1016/j.bpg.2013.03.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
46 Shenoy S. Primary small-bowel malignancy: update in tumor biology, markers, and management strategies. J Gastrointest Cancer. 2014;45:421-430. [PMID: 25339426 DOI: 10.1007/s12029-014-9658-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
47 Wu S, Chen JN, Zhang QW, Tang CT, Zhang XT, Tang MY, Li XB, Ge ZZ. A New Metastatic Lymph Node Classification-based Survival Predicting Model in Patients With Small Bowel Adenocarcinoma: A Derivation and Validation Study. EBioMedicine 2018;32:134-41. [PMID: 29908920 DOI: 10.1016/j.ebiom.2018.05.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
48 Sasaki J, Muneuchi I, Ushio K, Sochi C, Irie Y, Yoshizumi K, Hashimoto W. Brunner's Gland Adenocarcinoma in an Aged Western Gorilla (Gorilla gorilla). J Comp Pathol 2020;181:47-52. [PMID: 33288150 DOI: 10.1016/j.jcpa.2020.09.016] [Reference Citation Analysis]
49 Kitahara H, Honma Y, Ueno M, Kanemitsu Y, Ohkawa S, Mizusawa J, Furuse J, Shimada Y; Colorectal Cancer Study Group and Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD). Jpn J Clin Oncol 2019;49:287-90. [PMID: 30590606 DOI: 10.1093/jjco/hyy188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
50 Zhou YW, Xia RL, Chen YY, Ma XL, Liu JY. Clinical features, treatment, and prognosis of different histological types of primary small bowel adenocarcinoma: A propensity score matching analysis based on the SEER database. Eur J Surg Oncol 2021;47:2108-18. [PMID: 33849741 DOI: 10.1016/j.ejso.2021.03.260] [Reference Citation Analysis]
51 Safyan RA, Neugut AI. Anti-EGFR Therapy in Small Bowel Adenocarcinoma. Oncologist 2018;23:275-6. [PMID: 29438094 DOI: 10.1634/theoncologist.2017-0688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Patel PH, Likos-Corbett M, Doyle J, Kumar S, Bhogal RH. Node negative duodenal adenocarcinoma is associated with long-term patient survival following pancreaticoduodenal resection. ANZ J Surg 2022. [PMID: 35403794 DOI: 10.1111/ans.17694] [Reference Citation Analysis]
53 Vanoli A, Di Sabatino A, Furlan D, Klersy C, Grillo F, Fiocca R, Mescoli C, Rugge M, Nesi G, Fociani P, Sampietro G, Ardizzone S, Luinetti O, Calabrò A, Tonelli F, Volta U, Santini D, Caio G, Giuffrida P, Elli L, Ferrero S, Latella G, Ciardi A, Caronna R, Solina G, Rizzo A, Ciacci C, D'Armiento FP, Salemme M, Villanacci V, Cannizzaro R, Canzonieri V, Reggiani Bonetti L, Biancone L, Monteleone G, Orlandi A, Santeusanio G, Macciomei MC, D'Incà R, Perfetti V, Sandri G, Silano M, Florena AM, Giannone AG, Papi C, Coppola L, Usai P, Maccioni A, Astegiano M, Migliora P, Manca R, Martino M, Trapani D, Cerutti R, Alberizzi P, Riboni R, Sessa F, Paulli M, Solcia E, Corazza GR. Small Bowel Carcinomas in Coeliac or Crohn's Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer Italian Consortium.J Crohns Colitis. 2017;11:942-953. [PMID: 28333239 DOI: 10.1093/ecco-jcc/jjx031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
54 Zenali M, Overman MJ, Rashid A, Broaddus RB, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013;44:2792-2798. [PMID: 24139211 DOI: 10.1016/j.humpath.2013.07.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
55 Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer. 2014;50:1740-1746. [PMID: 24797764 DOI: 10.1016/j.ejca.2014.04.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
56 Lee DW, Lee KH, Kim TY, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative Chemotherapy. Nutr Cancer 2016;68:750-5. [PMID: 27282771 DOI: 10.1080/01635581.2016.1180413] [Reference Citation Analysis]
57 Giuffrida P, Vanoli A, Arpa G, Bonometti A, Luinetti O, Solcia E, Corazza GR, Paulli M, Di Sabatino A. Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current Knowledge. Cancers (Basel) 2018;11:E31. [PMID: 30597986 DOI: 10.3390/cancers11010031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
58 Legué LM, Simkens GA, Creemers GM, Lemmens VEPP, de Hingh IHJT. Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon. Eur J Cancer 2017;87:84-91. [PMID: 29132061 DOI: 10.1016/j.ejca.2017.10.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
59 Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013;10:534-544. [PMID: 23897080 DOI: 10.1038/nrclinonc.2013.132] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
60 Meijer LL, Strijker M, de Bakker JK, Toennaer JG, Zonderhuis BM, van der Vliet HJ, Wilmink H, Verheij J, Daams F, Busch OR, van Grieken NC, Besselink MG, Kazemier G. Clinical outcomes of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma. World J Gastrointest Oncol 2020; 12(3): 347-357 [PMID: 32206184 DOI: 10.4251/wjgo.v12.i3.347] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Wang L, Song Q, Li J, Chen X. S-1 treatment leading to complete remission of advanced duodenal adenocarcinoma: A case report. Mol Clin Oncol 2015;3:1184-6. [PMID: 26623074 DOI: 10.3892/mco.2015.607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
62 de Bree E, Rovers KP, Stamatiou D, Souglakos J, Michelakis D, de Hingh IH. The evolving management of small bowel adenocarcinoma. Acta Oncologica 2018;57:712-22. [DOI: 10.1080/0284186x.2018.1433321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
63 Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan W, Baylin SB, Wolfgang CL, Ahuja N. Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. PLoS One 2016;11:e0162929. [PMID: 27643594 DOI: 10.1371/journal.pone.0162929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
64 Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 2017;123:1011-7. [PMID: 27859010 DOI: 10.1002/cncr.30445] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
65 Akce M, Jiang R, Zakka K, Wu C, Alese OB, Shaib WL, Behera M, El-Rayes BF. Clinical Outcomes of Small Bowel Adenocarcinoma. Clin Colorectal Cancer 2019;18:257-68. [PMID: 31606297 DOI: 10.1016/j.clcc.2019.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
66 Wang FS, Gao ZJ, Liu YF. Recent advances in diagnosis and treatment of primary duodenal tumors. Shijie Huaren Xiaohua Zazhi 2014; 22(34): 5221-5227 [DOI: 10.11569/wcjd.v22.i34.5221] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 González I, Goyal B, Xia MD, Pai RK, Ma C. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. Human Pathology 2019;85:18-26. [DOI: 10.1016/j.humpath.2018.10.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
68 Dai ZH, Wang QW, Zhang QW, Yan XL, Aparicio T, Zhou YY, Wang H, Zhang CH, Zaanan A, Afchain P, Zhang Y, Chen HM, Gao YJ, Ge ZZ. Personalized four-category staging for predicting prognosis in patients with small bowel Adenocarcinoma: an international development and validation study. EBioMedicine 2020;60:102979. [PMID: 32980692 DOI: 10.1016/j.ebiom.2020.102979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]